Literature DB >> 32852635

Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria.

Xi Xu1, Xingyu Pu1, Li Jiang2, Yang Huang1, Lunan Yan1, Jiayin Yang1, Tianfu Wen1, Bo Li1, Hong Wu1, Wentao Wang1.   

Abstract

BACKGROUND: How much difference there is between hepatic resection (HR) combined with intraoperative radiofrequency ablation (RFA) and living donor liver transplantation (LDLT) in treatment of multifocal hepatocellular carcinomas (HCCs) remains unclear. This study compared outcomes for patients with multifocal HCCs meeting the University of California San Francisco (UCSF) criteria treated by LDLT or HR + RFA.
METHODS: A total of 126 consecutive Child-Pugh A patients with multifocal HCCs meeting the UCSF criteria, who underwent LDLT (n = 51) or HR + RFA (n = 75), were included. Propensity score (PS) matching was performed to adjust for baseline differences. Overall survival (OS) and recurrence-free survival (RFS) were calculated, and subgroup, multivariate and nomogram analyses were performed.
RESULTS: LDLT provided significantly better OS and RFS than did HR + RFA before and after PS matching and reduced the dropout rate on waiting list, but HR + RFA was more convenient, less invasive and less cost. Patients with all lesions located in the same lobe had better OS and RFS than those located in the different lobes after HR + RFA. Multivariate and nomogram analyses revealed that HR + RFA, alpha-fetoprotein ≥ 400 ng/mL, the major tumour size > 3 cm and microvascular invasion were independent predictors of poor prognosis.
CONCLUSION: For Child-Pugh A patients with multiple HCCs meeting the UCSF criteria, LDLT may offer significantly better long-term results than did HR + RFA, and HR + RFA may still be considered as an acceptable curative therapy for those without considering transplantation or as a bridge treatment for a patient, with a plan for transplantation in the future.

Entities:  

Keywords:  Hepatic resection; Hepatocellular carcinoma; Living donor liver transplantation; Multifocal tumours; Radiofrequency ablation; UCSF criteria

Year:  2020        PMID: 32852635     DOI: 10.1007/s00432-020-03364-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes.

Authors:  Tan To Cheung; Kelvin K Ng; Kenneth S Chok; See Ching Chan; Ronnie T Poon; Chung Mau Lo; Sheung Tat Fan
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

2.  Global trends and predictions in hepatocellular carcinoma mortality.

Authors:  Paola Bertuccio; Federica Turati; Greta Carioli; Teresa Rodriguez; Carlo La Vecchia; Matteo Malvezzi; Eva Negri
Journal:  J Hepatol       Date:  2017-03-21       Impact factor: 25.083

3.  Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.

Authors:  S A Curley; F Izzo; L M Ellis; J Nicolas Vauthey; P Vallone
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

4.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.

Authors:  Kai Feng; Jun Yan; Xiaowu Li; Feng Xia; Kuansheng Ma; Shuguang Wang; Ping Bie; Jiahong Dong
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

5.  Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatectomy.

Authors:  D Elias; A Goharin; A El Otmany; J Taieb; P Duvillard; P Lasser; T de Baere
Journal:  Eur J Surg Oncol       Date:  2000-12       Impact factor: 4.424

6.  Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.

Authors:  Christophe Duvoux; Françoise Roudot-Thoraval; Thomas Decaens; Fabienne Pessione; Hanaa Badran; Tullio Piardi; Claire Francoz; Philippe Compagnon; Claire Vanlemmens; Jérome Dumortier; Sébastien Dharancy; Jean Gugenheim; Pierre-Henri Bernard; René Adam; Sylvie Radenne; Fabrice Muscari; Filomena Conti; Jean Hardwigsen; Georges-Philippe Pageaux; Olivier Chazouillères; Ephrem Salame; Marie-Noelle Hilleret; Pascal Lebray; Armand Abergel; Marilyne Debette-Gratien; Michael D Kluger; Ariane Mallat; Daniel Azoulay; Daniel Cherqui
Journal:  Gastroenterology       Date:  2012-06-29       Impact factor: 22.682

7.  Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal.

Authors:  Sima Blank; Qin Wang; M Isabel Fiel; Wei Luan; Ki Won Kim; Hena Kadri; John Mandeli; Spiros P Hiotis
Journal:  Ann Surg Oncol       Date:  2014-03       Impact factor: 5.344

8.  Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy?

Authors:  Rene Adam; Prashant Bhangui; Eric Vibert; Daniel Azoulay; Gilles Pelletier; Jean-Charles Duclos-Vallée; Didier Samuel; Catherine Guettier; Denis Castaing
Journal:  Ann Surg       Date:  2012-12       Impact factor: 12.969

Review 9.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

Authors:  Jordi Bruix; Maria Reig; Morris Sherman
Journal:  Gastroenterology       Date:  2016-01-12       Impact factor: 22.682

10.  Results of liver resection in combination with radiofrequency ablation for hepatic malignancies.

Authors:  R M Eisele; J Zhukowa; S Chopra; S C Schmidt; U Neumann; J Pratschke; G Schumacher
Journal:  Eur J Surg Oncol       Date:  2009-09-01       Impact factor: 4.424

View more
  1 in total

1.  Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation.

Authors:  Lianjie Bai; Xinping Wang; Shenglong Shi; Jian Gao; Xing Li; Ying Wang; Maitao Jiang; Chunlei Zheng; Huilin Liu
Journal:  J Healthc Eng       Date:  2021-12-20       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.